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Summary.-Intact human bone marrow cells from 7 patients with myelomatosis
were inoculated intravenously into adolescent CBA mice rendered immunologically
deficient bythymectomy followed by total bodyirradiation (600 rad). Each inoculum
of human myeloma marrow cells and subsequent passages of intact mouse marrow
and spleen cells resulted in the presence of morphological changes in the marrow,
spleen and peripheral blood of a proportion of these mice which were closely similar
to those seen in the human donor. A substantial amount of human immunoglobulin
(IgG and IgA) was detected in the sera of some of the mice showing morphological
changes. Mice prepared identically but remaining uninoculated or receiving intact
human bone marrow cells from 3 patients with no evidence of haematological malig-
nancy showed none of these changes when examined after similar intervals.
There are at least 3 possible explanations for these findings: in mice receiving
human myeloma marrow cells they might be accounted for by the persistence and
replication of these cells in an immunologically deficient host. In mice receiving a
first, second or third passage of abnormal mouse marrow and spleen cells they might
similarly be accounted for by the survival and multiplication of a stem cell secreting
both mouse and human immunoglobulins. Alternatively, the mouse stem cells may
in some way have been transformed following infection by a transmissible agent
originally present in the myeloma donor marrow cells.
RATS, mice and hamsters rendered
immunologically deficient by treatment
with cortisone or cyclophosphamide
(Toolon, 1953, 1958; Handler, Davies and
Sommers, 1956; Patterson, Patterson and
Chute, 1957; Kaufman and Lichtenauer,
1967) or by the use of anti-lymphocyte
serum (Lance and Medawar, 1968; Phillips
and Gazet, 1967) have been widely used to
obtain xenografts from a wide variety of
animal and human tumours. More pro-
longed survival of successful grafts has
been obtained using anti-lymphocyte
serum and irradiation in mice which had
previously been thymectomized (Phillips
and Gazet, 1968, 1970; Sheard, Double
and Berenbaum, 1971). This paper de-
scribes the results ofa study in which mice
rendered immunologically deficient by
thymectomy followed by total body
irradiation (600 rad) were used to provide
appropriate conditions for the study of
human haematological malignancy in the
experimental animal. The general plan
and conduct of experiments in which we
have usedhumanmyelomatosis toexempli-
fy our findings are given in Fig. 1.
MATERIAL AND METHODS
Humtan bone marrow cell aspirates.-The
donor characteristics and a numerical refer-
ence to aspirates ofhuman bone marrow used
in our experiments are given in Table I.
Human bone marrow, cells and the harvests
of mouse marrow and spleen cells used in
subsequent mouse passages, were suspended
in heparin saline (5 i.u./ml).
Experimental animals.-Female CBA mice
were thymectomized at 12 weeks of age; this
was followed 2 weeks later by total body
irradiation (600 rad) within 4 hours before theD. N. MITCHELL, R. J. W. REES AND A. J. SALSBURY
MYELOMATOSIS CONTROLS
Inoculated Uninoculated
Human myeiloma marrow Normal human marrow
cells cells
\\ ~~//
Intravenous inoculation of intact
human cells
into
Immunologically deficient mice (T/600 rad) Controls:
4, 4, No in
Intravenous inoculation of a first
passage of mouse cells
into
T/600 rad)
jection
Immunologically deficient mice (T/600 rad) - Controls: (T/600 rad)
, 1 No injection
Intravenous inoculation of a second
passage of mouse cells
into
Immunologically deficient mice (T/600 rad) Controls: (T/600 rad)
4, No injection
Intravenous inoculation of a third
passage of mouse cells
into
Immunologically deficient mice (T/600 rad) - - - - - - - - - - - - Controls: (T/600 rad)
I No injection
FIG. 1.-General plan and conduct of experiments.
TABLE I.-Bone Marrow Aspirates
Donor No. % Total nucleated count
Control Plasma cells
IC 1-8
2C 0-8
3C 0-6
Myelomatosist
iM
2M
2MA
3M
4M
5M
6M
7M
8M
Plasma and myeloma cells
70
19
25
70
15
40
85
60
90
t IgG Myeloma, except 3M (IgA).
intravenous injection of human myeloma
marrow cells or ofthe passage ofpooled mouse
marrow andspleen cells. Inorientating experi-
ments, similarly prepared mice were given
900 rad total body irradiation (T/900 rad)
with subsequent partial syngeneic mouse
bone marrow cell replacement before inocula-
tion. In some ofthese mice anti-lymphocyte
serum (ALS) wasusedaswell. Themicewere
observed closely and the onset of sickness
recorded. Moribundmicewerekilled, usually
9-16 days following inoculation, and from
each mouse impression smears were made
from bone marrow and spleen and films of
peripheral blood. These were stained with
May-Grunwald-Giemsa stain. Samples of
spleen and liver were fixed for histological
assessment. Sections were subsequently
stained with haematoxylin and eosin. Blood
was obtained by cardiac puncture for serum
analysis of human IgG, IgA and IgM, using
" Tri-Partigen " and " LC-Partigen " im-
munodiffusionplates. Exactlysimilarassess-
ments were made from uninoculated and
inoculated control mice killed within the
same period of time. All assessments were
undertaken from coded preparations when
the observers were unaware of the inoculum
or treatment. No specimens were examined
from mice found dead, to avoid false readings
due to autolysis, but a note was made of the
date of death. In all smears and sections
particular note was made of any excess of
plasma cells and ofthe presence or absence of
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abnormal cells resembling myeloma cells in
the human donor.*
RESULTS
Inoculated and uninoculated controls
Inoculation of intact normal human
bone rnarrow cells. Of 26 mice in these
3 experiments, 12 each received 4 25 x 106
cells from donor 1C; 6 received 11 X 1_06
cells from donor 2C and 8 received
1P0 x 106 from donor 3C. None of the
mice in these experiments showed evidence
of sickness following inoculation. A total
of 18 mice were killed 14-18 days after
inoculation; [8 (1C), 4 (2C) and 6 (3C)].
In all the animals the marrow and spleen
showed evidence of erythropoiesis, but
none showed infiltration by abnormal
cells. Sera from 3 of the 8 mice inocu-
lated from donor 1, from each ofthe 4 mice
from donor 2, and from 2 of the 6 mice
from donor 3 showed traces ofhuman IgG
or IgA, or both (less than 5 mg/100 ml).
First passage of mouse marrow and
spleen cells originating from donors 1C, 2C
and 3C. Intact pooled marrow and
spleen cells from each of the 3 groups of
mice inoculated 18-24 days previously
with normal intact human bone marrow
cells (IC, 2C and 3C) were inoculated
intravenously into 3 further groups of
identically prepared mice. Of 16 mice in
these 3 experiments, 4 received 8-6 X 106
cells, (1C); 6 received 1-6 x 106 (2C) and
6 received 5 x 106 (3C). A total of
15 mice were killed 16 days after inocula-
tion: [4 (1C), 6 (2C) and 5 (30)]. No sick-
ness was observed but 1 mouse was found
dead when the remainder were killed on
the 16th day. In all 15 animals the
marrow and spleen showed evidence of
erythropoiesis but none showed infiltra-
tion by abnormal cells. No human im-
munoglobulin was detected in the sera
from these 15 mice.
Uninoculated controls-.In identically
prepared but uninoculated mice from the
same stock which were examined after
similar intervals, one mouse (collateral to a
second passage derived from donor 5M)
died 33 days after irradiation. Others
showed only transient sickness, usually
7-10 days following irradiation. All of
9 mice examined 13-14 days after total
body irradiation (600 rad) showed marked-
ly hypoplastic marrows with no infiltration
by abnormal cells. The spleens of 8 of
these 9 mice showed active erythropoiesis
but in none was there evidence of infiltra-
tion by abnormal cells; plasma cells seen in
3 of the spleens of these mice were few in
number and widely scattered. Haemo-
poiesis was clearly apparent in the marrow
and spleen ofthe 6 mice examined after an
interval of 98-365 days. In these, the
marrow was normal and active and the
spleen showed germinal follicles with no
infiltration by abnormal cells. No human
immunoglobulin was detected in the serum
from these 15 mice.
Inoculation of intact human myeloma
marrow cells from donors 1M and 2M
In initial experiments of orientation of
a total of 22 mice (3 groups: T/900rad
without partial syngeneic mouse bone
marrow cell replacement, T/900 rad with
partial syngeneic bone marrow cell re-
placement and ALS) received 2-6-
4.9 x 106 myeloma marrow cells from
donor IM or 2M. Three mice (T/900 rad
only) died at intervals of 7, 8 and 9 days
respectively, and 6 (4, T/900 rad only,
1, T/900 rad with syngeneic mouse marrow
and 1 T/900 rad with syngeneic mouse
marrow and ALS) were killed when sick or
moribund 9-13 days after inoculation.
In each of the 4 mice (T/900 rad only) the
marrow was grossly hypoplastic and
virtually acellular, but the spleen showed
extensive infiltration by plasma and
primitive lymphoid cells, some in mitosis.
Erythropoiesis was present in the marrow
and spleen of each of the 2 mice killed
* Such abnormal cells were large (average 20-25 ,um in diameter), possessed nuclei with a fine chromatin
pattern, prominent nucleoli and abundant moderately basophilic cytoplasm with no evidence ofcytoplasmic
granules.
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TABLE II.-Findings after Prolonged Survival
Sites examined and
proportion with
abnormal cells
Donor Mouse No. of
No. model Inoculum cells
IM *T (900 rad) Human 2 6 x106
myeloma
marrow
cells
1M *T (900 rad) Human 2 6 x106
and ALS myeloma
marrow
cells
2M *T (900 rad) Human 4*9 x106
myeloma
marrow
cells
2M *T (900 rad) Human 4 9 x 106
and ALS myeloma
marrow
cells
t3M T (600rad) 1st 12xl06
passage
abnormal
mouse
cells
7M T (600 rad) Human 2-8xl106
myeloma
marrow
cells
Months
survived
12
Bone
marrow Spleen
2/4 2/4
11 1/2 1/2
Blood
0
Human immunoglobulin
(mg/100 ml)
IgG IgA IgM
0 0 0
0 0 0 0
7 1/4 1/4 1/4 0 0 0
7 0/3 1/3 0 0 0 0
5 0/3 1/3 0 1, (120) 1, 31 0
15 2/3 2/3 0 0 0 0
* With partial syngeneic mouse marrow cell replacement, before inoculation.
t IgA myeloma.
(1, T/900 rad with syngeneic mouse mar-
row and 1 T/900 rad with syngeneic
mouse marrow and ALS) but neither
showed evidence of infiltration by ab-
normal cells. No attempt was made to
obtain serum from these 6 moribund mice.
The remaining 13 mice survived and are
referred to later (Table II).
Inoculation of intact human myeloma
marrow cells from donors 2MA, 3M, 4M,
5M, 6M, 7M and 8M
In these experiments mice were pre-
pared by thymectomy followed by total
body irradiation (600 rad) but without
syngeneic mouse marrow cell replacement
(T/600 rad). Of 1Omicereceiving 5 x 106
myeloma marrow cells from a second
aspirate from donor 2M (2MA), 3 died after
12 days and the remaining 7 were killed
when sick or moribund 12-13 days after
inoculation; all 7 showed infiltration of
marrow and spleen by abnormal cells.
No human immunoglobulin was detected
in the sera from these 7 mice.
Five mice were inoculated with
3.7 X 106 myeloma marrow cells from
donor 3M which showed the characteristics
of an IgA myeloma. All 5 mice were
killed when sick or moribund 13 days after
inoculation. No cells resembling plasma
or myeloma cells were seen in the blood of
any of these animals; infiltration by
abnormal cells was found in the marrow in
4 and in the spleen in all 5. It was
interesting to note that some ofthe plasma
cells possessed " flaming " cytoplasm, an
appearance said to be characteristic of
human IgA myeloma. No human
immunoglobulin was detected in the sera
from these 5 mice.
Of 7 mice inoculated with 2-2 x 106
myeloma marrow cells (donor 4M), 5 died
unexpectedly 13 days afterinoculation and
2 were killed when moribund on the 14th
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day. Peripheral blood smears from both
these mice were normal but in each the
marrow and spleen was infiltrated by
abnormal cells. Human immunoglobulin
(IgA, < 5 mg/100 ml) was detected in the
serum from each of these mice.
Of 8 mice inoculated with 3-1 x 106
myeloma marrow cells (donor 5M), 1 died
and 6 were killed when sick or moribund
11 days after inoculation. Abnormal cells
were found in the blood and marrow of
4 mice and in the spleens of all 6 (Fig. 2).
In the serum from 5 of these mice human
IgG (16-60 mg/100 ml), and in 1 human
IgA (27 mg/100 ml), were detected.
The 11 mice receiving 2 9 x 106 and
3.4 x 106 myeloma marrow cells from
donors 6M and 8M respectively showed no
sickness and were killed 13 days after
inoculation. Abnormal cells were present
in the blood of 3 and in the marrow and
the spleens of all 11 mice. The serum of
7 of these 11 mice showed the presence of
human IgG (19, 19 and 21 mg/100 ml and
in 4, <5 mg/100 ml).
First passage of abnormal mouse marrow
and spleen cells originating from donors
2MA, 3M, 4M, 5M and 6M
The 5 mice receiving 6-6 x 106 intact
abnormal mouse marrow cells originating
from donor 2M (2MA) were killed when
sick or moribund 12 days after inoculation.
Peripheral blood smears were not examin-
ed but in all 5 mice the marrow and spleens
were infiltrated by abnormal cells. Hu-
man immunoglobulin was not detected in
the sera from these 5 mice.
Four mice received 1-2 x 106 intact
pooled abnormal mouse marrow and
spleen cells (3M). One mouse was killed
when sick 9 days later. The peripheral
blood, marrow and spleen were heavily
FIG. 2.-Marrow film to show several plasma cells (arrowed P) and primitive cells (arrowed M) from
mouse injected with myeloma marrow cells from donor 5M. May-Gruinwald-Giemsa x 915.
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infiltrated by abnormal cells but human
immunoglobulin was not detected in the
serum.
Six mice received 2-5 x 106 intact
pooled abnormal mouse marrow and spleen
cells (4M). Although not apparently sick,
these 6 mice were killed 21 days after
inoculation. In 2 the spleens and blood
smears, and in 1 the marrow, showed
abnormal cells. No human immuno-
globulin was detected in the serum from
these 6 mice.
Of 5 mice receiving 2-7 x 106 intact
pooled abnormal mouse marrow and spleen
cells (5M) 1 died and 4 became sick and
were killed 10 days after inoculation.
Peripheral blood smears from each ofthese
4 mice showed the presence of abnormal
cells; such cells were found in the marrow
and spleens of 3. Human immuno-
globulins were not detected in the sera
from these 4 mice. The 5 receiving
6 1 x 106 intact pooled abnormal mouse
marrow and spleen cells (6M) did not
appear sick, but were killed 16 days after
inoculation. In 3 the marrow, and in 1
the spleen and peripheral blood smear,
showed the presence of abnormal cells.
In the serum from 1 of these mice, human
IgG (42 mg/lO0 ml) and human IgA
(< 5 mg/100 ml) were detected.
Second and third passage ofabnormal intact
mouse marrow and spleen cells originating
from donor 5111
The 5 mice receiving a second passage
of pooled abnormal mouse marrow and
spleen cells (9.4 X 106) became sick and
were killed 11 days after inoculation. In
4, peripheral blood smears and marrow,
and in all 5 the spleen, contained abnormal
cells. No human immunoglobulin was
detected in the sera from these 4 mice.
The 5 mice receiving a third passage of
pooled intact mouse marrow and spleen
cells (3 3 x 106) became sick and were
killed 12 days after inoculation. In 4,
peripheral blood smears showed the pre-
sence of abnormal cells, and the marrow
and spleens were heavily infiltrated by
abnormal cells in all 5. In the serum
from 1 of these 5 mice, human immuno-
globulin (IgG 23 mg/100 ml) was detected.
Findings in surviving mice killed after a
prolonged intervalfollowing inoculation
The results following inoculation of
intact human myeloma marrow cells in
mice which had been prepared by adol-
escent thymectomy and receiving 900 rad
followed by syngeneic mouse marrow cell
replacement (T/900 rad), with or without
the addition ofALS, and in surviving mice
prepared by adolescent thymectomy and
receiving 600 rad without syngeneic mouse
bone marrow cell replacement (T/600 rad)
are given in Table II. Of 4 mice (T/900
rad and BM) killed 12 months after receiv-
ing myeloma marrow cells from donor IM,
none showed abnormal cells in peripheral
blood smears. In 2, abnormal cells were
present in the marrow and spleen. No
human immunoglobulin was detected in
the serum of these 4 mice. Neither of the
2 mice (T/900 rad and BM and ALS) killed
11 months after receiving myeloma mar-
row cells from donor 1M showed abnormal
cells in peripheral blood smears but in
1 mouse abnormal cells were present in
marrow and spleen. Human immuno-
globulin was not detected in the serum
from either mouse. Of 4 mice (T/900 rad
and BM) killed 7 months after receiving
intact human mveloma marrow cells from
donor 2M, 1 showed abnormal cells
in peripheral blood smears and in 1 the
marrow and spleen were infiltrated by
abnormal cells. No human immuno-
globulin was detected in the sera from
these 4 mice. Of 3 mice (T/900 rad and
BM and ALS) killed 7 months after
receiving intact myeloma marrow cells
from donor 2M, 1 had abnormal cells
in the spleen; this mouse also showed
lymphoid infiltration of the portal tracts
of the liver. No human immunoglobulin
was detected in the sera from these 3 mice.
Of 3 mice killed 5 months after surviv-
ing a first passage of pooled intact abnor-
mal mouse marrow and spleen cells
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FIG. 3.-Smear of spleen to show " flaming " cytoplasm in a plasma cell from an apparently healthy
surviving mouse killed 5 months after intravenous inoculation with a first passage ofpooled mouse
marrow and spleen cells originating from donor 3M (IgA myeloma). May-Grunwald-Giemsa
x 1350.
originating from donor 3M, no abnormal
cells were found in peripheral blood smears
orbone marrow, but in 1 the spleen showed
an excess of plasma cells and there was
lymphoid infiltration ofthe portal tracts of
the liver. Some of the plasma cells again
exhibited " flaming " cytoplasm (Fig. 3).
Human immunoglobulin (IgG 120 mg/
100 ml; IgA 31 mg/100 ml) was detected
in the serum from this mouse.
Finally, 3 mice were killed 15 months
after receiving intact myeloma marrow
cells from donor 7M. None showed
abnormal cells in peripheral blood smears,
but in 2 the bone marrow and spleens
showed the presence of abnormal cells.
No human immunoglobulin was detected
in the sera from these 3 mice.
DISCUSSION
These experiments show that mice pre-
pared by adolescent thymectomy followed
by total body irradiation (600 rad) can be
used to provide suitable conditions for the
study of human myelomatosis and other
haematological malignancies (Mitchell,
Rees and Salsbury, 1972). Thus, within
10 to 30 days following the inoculation of
intact human myeloma marrow cells a
considerable proportion of mice so pre-
pared yielded cytological and serological
changes closely similar to those found in
the human donor. These findings pre-
sumably result from the initial acceptance
of a graft of human malignant cells and
their subsequent replication within the
immunologically deficient mouse model.
Our findings in mice killed after a short
interval following inoculation are closely
similar to those of Phillips and Gazet
(1970), who found that progressive growth
of transplantable human carcinoma cell
lines would grow for at least one month in
ALS treated mice which had previously
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been thymectomized. Similarly, Beren-
baum (1971) transplanted human tumours
into mice which had been thymectomized,
irradiated and treated with antilympho-
cyte serum; about one third ofthe tumours
grew for several weeks, with retention of
the histological appearances seen in man.
The possibility that the histological
changes found in mouse bone marrow or
spleen might result from adolescent thy-
mectomy or totalbodyirradiation irrespec-
tive ofthe inoculation of human myeloma
marrow cells, has been critically examined.
Thus, among identically prepared but
uninoculated mice from the same stock
which served as collateral controls to mice
receiving human myeloma marrow cells,
the marrows were hypoplastic but showed
no infiltration by abnormal cells when
examined after similar intervals. The
spleens ofthese uninoculated mice showed
active erythropoiesis, but in none was
there evidence of infiltration by abnormal
cells; plasma cells were occasionally seen
but when present were few in number and
widely scattered. Similarly, the marrows
and spleens of all mice identically pre-
pared but receiving normal human bone
marrow cells or a first passage of pooled
mouse bone marrow and spleen cells
originating from these mice, showed
evidence of active erythropoiesis and the
splenic appearances were closely similar to
those described by Till and McCulloch
(1961).
The presence of human immuno-
globulin (IgG and IgA), as detected by
immunodiffusion of the undiluted sera of
mice 11 to 17 days following the inocula-
tion of intact human myeloma marrow
cells, might be attributable to the transfer
of human serological components in the
inoculum. This explanation could
account entirely for the serological findings
in these mice; it is relevant that traces of
human IgG and IgA were also found in the
sera of mice showing no infiltration by
abnormal cells and which were bled after
similar intervals following the inoculation
of intact and normal human marrow cells.
Cytological changes largely indistin-
guishable from those present in the human
donor were found in the marrow, spleen
and peripheral blood of a substantial
proportion of mice receiving a first,
second or a third passage of abnormal
mouse marrow and spleen cells originated
from no less than 5 separate human donors
with myelomatosis. Moreover, human
immunoglobulin (IgG 42 mg/100 ml; IgA,
< 5 mg/100 ml) was detected in the serum
of one mouse receiving a first passage of
abnormal mouse marrow and likewise in
the serum of one mouse receiving a third
passage of abnormal mouse marrow and
spleen cells originating from a different
human myeloma donor. These niouse
sera have been examined against a number
of class specific antisera and the presence
of human immunoglobulin has been con-
firmed. Similarly, it is of interest that a
proportion ofapparently healthy surviving
mice receiving intact human myeloma
marrow cells from each of 3 separate
donors, again showed the presence of
changes in marrow, spleen or peripheral
blood closely similar to those seen in the
human donor when killed 7 to 15 months
after inoculation. The findings in one
other of these mice remaining apparently
healthy after receiving a first passage of
abnormal mouse marrow and spleen cells
originating from donor 3M (IgA myeloma),
are of especial interest. When killed
5 months after inoculation this mouse
showed abnormal cells in the spleen; some
of the plasma cells seen exhibited flaming
cytoplasm (Fig. 3). Again, human im-
munoglobulin (IgG 120 mg/100 ml; IgA
31 mg/100 ml) was detected in the serum
from this mouse.
These findings certainly provide evi-
dence of the ability of mice so prepared to
support a graft ofhuman myeloma marrow
cells. Although various lines of human
tumour cells have been established which
are indefinitely transplantable in im-
munosuppressed animals, the transplanta-
tion of tumours freshly obtained from
patients is much less successful. For
example, Phillips and Gazet (1970) found
that only 12 of 66 human tumours which
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they attempted to transplant to thymecto-
mized ALS treated mice, appeared viable
25 days after transplantation. It would
therefore seem unlikely that our findings
can be accounted for entirely by the per-
sistence and multiplication of the injected
human cells, although we have been
unable to find any previous account ofthe
inoculation of human myeloma marrow
cells in the experimental animal.
An alternative explanation might be
the possibility that cell hybridization may
occur between human myeloma marrow
and normal mouse cells, thus giving rise to
other cells secreting myeloma protein.
Such in vivo hybridization would be similar
to that described by Wiener, Klein and
Harris (1973). In this context, the find-
ings of Schwaber and Cohen (1973), who
showed by cell culture that a hybrid clone
resulting from the fusion of a myeloma
mouse cell with a human lymphocyte
(initially shown to produce no immuno-
globulin) subsequently secretes both
human and mouse immunoglobulins, are
highly relevant. Finally, there remains
the possibility that in a proportion of the
immunologically deficient mice in our
experiments the mouse marrow cells
became infected by an agent from the
human myeloma marrow cells following
their initial acceptance as a graft (Mitchell,
Rees and Salsbury 1971, 1972).
Further detailed studies designed to
establish more precisely the most likely
explanation for our present findings are
currently in progress.
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